ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L8

Overexpression of Set1 at the Promoter Contributes to cAMP Response Element Modulator Alpha Overexpression in Systemic Lupus Erythematosus

Qing Zhang1, Huilin Zhang2, Hai Long1, Jieyue Liao3, Ming Zhao1, Xiangning Qiu1 and Qianjin Lu1, 1Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, 2Nursing Department, Second Xiangya Hospital, Central South University, Changsha, China, 3Department of Dermatology, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Histone Modification, T cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: ACR Late-Breaking Abstract Poster Session

Session Type: Late-Breaking Abstracts

Background/Purpose: In recent years, accumulating evidence has demonstrated that increased cAMP response element modulator α (CREMα) which contributes to IL-2 reduction and IL-17A overproduction in T cells plays an essential role in the pathogenesis of systemic lupus erythematosus (SLE). The aim of this study is to investigate what regulate CREMα expression in SLE.

Methods: CD4+ T cells were isolated from SLE patients and healthy controls. Histone H3 lysine 4 trimethylation (H3K4me3, a prevalent mark associated with transcription activation) enrichment at various gene promoters in CD4+ T cells from 5 SLE patients and 5 healthy controls was analyzed by chromatin immunoprecipitation (ChIP) microarray. Amounts of H3K4me3, Set1 and MLL1 (both are H3K4 methyltransferases) within the CREMα promoter were subsequently analyzed by ChIP and real-time PCR in CD4+ T cells from 15 SLE patients and 15 healthy controls. And CREMα mRNA levels were determined by real-time RT-PCR.

Results: In ChIP microarray data, we identified sharply increased H3K4me3 enrichment at the CREMα promoter of SLE CD4+ T cells relative to controls. Then by ChIP and real-time PCR experiments, we confirmed this result. Moreover, H3K4me3 enrichment at the promoter was positively correlated with CREMα mRNA levels in SLE CD4+ T cells. In addition, a striking increase was observed in Set1 binding, but no marked change in MLL1 binding at the CREMα promoter region in SLE CD4+ T cells compared to healthy controls. We also proved the levels of Set1 binding were positively correlated with H3K4me3 enrichment at the CREMα promoter, and positively correlated with CREMα mRNA levels. Knocking down Set1 with siRNA in SLE CD4+ T cells led to decreased Set1 binding and H3K4me3 enrichment at the CREMα promoter region, thus inhibiting the expression of CREMα.

Conclusion: Our findings suggest for the first time that increased Set1 binding up-regulates H3K4me3 enrichment at the CREMα promoter, which induces CREMα overexpression in SLE CD4+ T cells, and contributes to the development of SLE at last. These results can help elucidate the molecular pathogenesis of SLE, and provide a novel way and target for effective SLE therapy.


Disclosure:

Q. Zhang,
None;

H. Zhang,
None;

H. Long,
None;

J. Liao,
None;

M. Zhao,
None;

X. Qiu,
None;

Q. Lu,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/overexpression-of-set1-at-the-promoter-contributes-to-camp-response-element-modulator-alpha-overexpression-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology